This is mechanistically demonstrated in breast cancer models, where SFN, by activating the Nrf2 pathway, reduces the secretion of prostaglandin E2 (PGE2) from tumor cells, thereby triggering MDSCs to switch from an immunosuppressive to an immunogenic phenotype and inhibiting their expansion (76). The gene discussed is NFE2L2; the disease is neoplasm.